Orsini Diego, Narcisi Alessandra, Arcese Annalisa, Costanzo Antonio
Dermatology Unit, Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), University of Rome "La Sapienza", Rome, Italy.
Dermatology Unit, Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), University of Rome "La Sapienza", Rome, Italy
J Int Med Res. 2016 Sep;44(1 suppl):58-60. doi: 10.1177/0300060515593252.
Retrospective study to evaluate the incidence of infectious adverse events in patients with psoriasis treated with etanercept.
Patients with psoriasis or psoriatic arthritis who were treated with etanercept (50 mg, administered weekly via subcutaneous injection) for ≥48 weeks were retrospectively enrolled. Patients were screened for occult infections before treatment commenced, and then every 12 months thereafter. Minor (not requiring hospitalization and/or discontinuation of treatment) and major (requiring hospitalization and/or discontinuation of treatment) infectious events were recorded.
The study included 50 patients. Minor infectious events included self-limiting upper respiratory tract infections (six patients), lower urinary tract infections (one patient) and recurrent herpes simplex labialis (two patients). Major infections occurred in only two cases.
These data support the good safety profile of etanercept in patients with psoriasis or psoriatic arthritis.
进行回顾性研究以评估接受依那西普治疗的银屑病患者发生感染性不良事件的发生率。
回顾性纳入接受依那西普（50毫克，每周皮下注射给药）治疗≥48周的银屑病或银屑病关节炎患者。在治疗开始前以及之后每12个月对患者进行隐匿性感染筛查。记录轻微（无需住院和/或中断治疗）和严重（需要住院和/或中断治疗）感染事件。
该研究纳入了50例患者。轻微感染事件包括自限性上呼吸道感染（6例患者）、下尿路感染（1例患者）和复发性唇疱疹（2例患者）。仅2例发生了严重感染。
这些数据支持依那西普在银屑病或银屑病关节炎患者中具有良好的安全性。
